However, patients with mutant RAS tumor status had inferior progression-free survival (HR = 1.34, 95 percent CI, 1.07-1.6) and OS (HR = 1.25, 95 percent CI, 1.02-1.55) when administered Vectibix in combination with Folfox compared to Folfox alone...Additionally, the length of time during which people lived without their disease worsening (median progression-free survival, PFS) was more than doubled (23 months compared to 10.9 months, HR = 0.14, 95 percent CI 0.09-0.21, p < 0.0001) when compared to

The primary endpoint in Phase II will be progression-free survival

Syndax Pharmaceuticals Inc., of Waltham, Mass., said Phase II results published in the Journal of Clinical Oncology showed that HDAC inhibitor entinostat extended both progression-free survival (PFS) and overall survival when added to exemestane in postmenopausal women with estrogen receptor-positive breast cancer whose cancer had progressed after treatment with a nonsteroidal aromatase inhibitor

Eli Lilly and Co., of Indianapolis, said the Phase III PRELUDE study of enzastaurin, which explored the molecule as monotherapy in preventing relapse in patients with diffuse large B-cell lymphoma, failed to show a statistically significant increase compared to placebo in disease-free survival in patients at high risk of relapse following rituximab-based chemotherapy

Agenus Inc., of Lexington, Mass., said preliminary data from a Phase II trial showed that newly diagnosed glioblastoma multiforme (GBM) patients treated with Prophage G-100 (heat shock protein-peptide complex-96, HSPPC-96) vaccine plus the standard of care showed a 146 percent increase in progression-free survival (PFS) and a 60 percent increase in overall survival (OS) as compared to the standard of care alone...Additional analyses will evaluate progression-free survival, tumor response rates

Active Biotech, of Lund, Sweden, and Ipsen, of Paris, said they now plan to conduct the primary progression-free survival analysis for the 10TASQ10 global Phase III trial of tasquinimod in 2014, at the same time as the first interim overall survival analysis, when more mature data are available...The primary endpoint is to demonstrate a median progression-free survival increase from 50 percent to 65 percent

The primary endpoint of the trial, which compares ibrutinib monotherapy to ofatumumab, will be improvement in progression-free survival

Northwest Biotherapeutics Inc., of Bethesda, Md., said that a patient treated with DCVax-L for glioblastoma multiforme in 2002 has celebrated his 10th anniversary of cancer-free survival

OncoGenex Pharmaceuticals Inc., of Vancouver, British Columbia, said an investigator-sponsored, randomized, double-blind, placebo-controlled Phase II trial of OGX-427 in non-small-cell lung cancer (NSCLC) will be initiated to evaluate whether the drug in combination with carboplatin and pemetrexed can extend progression-free survival

The median progression-free survival was significantly higher with Velcade-based induction therapy compared to non-Velcade-based: 35.9 months compared to 28.6 percent, respectively (p < 0.0001), at a median follow up of 37 months

Further data presented showed that patients with normal levels of alpha-1-acid glycoprotein (AAG) had a longer median overall survival (20.2 months vs. 4.5 months), improved median event-free survival (5.3 months vs. 2.4 months) and a greater overall response rate (24 percent vs. 0 percent) compared to patients with elevated AAG...The primary endpoint of that cohort was to obtain a 40 percent progression-free survival rate at four months of treatment

Preliminary analysis suggested that AXL1717 has a similar progression-free survival rate as docetaxel after 12 weeks...Study endpoints include progression-free survival, objective response rate, median overall survival and evaluation of pharmacodynamics tumor markers, in addition to safety

The open-label, pivotal trial will enroll 400 subjects at about 80 sites in Australia, Canada, China, Europe, Latin America and the U.S. The primary endpoint is progression-free survival, and secondary endpoints include overall survival and safety...The primary outcome is progression-free survival

Secondary objectives of the trial, for which data were not released, include progression-free survival, overall survival, safety and tolerability

Three patients have met the primary endpoint of immune-related progression free survival at six months, and two patients are progressing to the extension study

The study also will assess secondary measures of clinical benefit, including progression-free survival, objective response rate and overall survival at six months and 12 months

The primary endpoint is rate of progression-free survival at 16 weeks, with secondary endpoints of objective response rate, duration of response and evaluation of pharmacodynamic tumor markers

Patients with all target tumor lesions positive as assessed by etarfolatide imaging, FR(100 percent) experienced substantial progression-free survival compared to patients with 10 percent to 90 percent of target lesions positive for folate receptor, FR(10-90 percent), when treated with single-agent vintafolide

The primary endpoint of the study is progression-free survival, and results are expected in early 2014...The objectives are to measure progression-free survival and overall survival, while safety parameters, quality-of-life impact, manufacturing quality and additional laboratory assessments also will be investigated